Northwestern Mutual Wealth Management Co. Has $58.56 Million Position in IQVIA Holdings Inc. $IQV

Northwestern Mutual Wealth Management Co. boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 259,800 shares of the medical research company’s stock after acquiring an additional 8,072 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in IQVIA were worth $58,561,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of IQV. Boston Partners acquired a new stake in IQVIA in the 3rd quarter valued at $676,698,000. AQR Capital Management LLC boosted its holdings in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Citigroup Inc. boosted its holdings in IQVIA by 108.2% during the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after acquiring an additional 475,557 shares during the last quarter. Invesco Ltd. boosted its holdings in IQVIA by 15.3% during the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in IQVIA by 41.6% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,132,072 shares of the medical research company’s stock worth $255,180,000 after acquiring an additional 332,505 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IQV shares. Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Finally, BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $225.69.

IQVIA Stock Up 0.5%

Shares of NYSE IQV opened at $182.03 on Friday. IQVIA Holdings Inc. has a 12 month low of $136.41 and a 12 month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $30.38 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.74 and a beta of 1.18. The business has a 50-day moving average of $170.34 and a 200-day moving average of $196.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.